Journal
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 7, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40425-019-0686-x
Keywords
CLL; CAR T cells; Ibrutinib
Categories
Ask authors/readers for more resources
Experience in the use of CAR T cells to treat CLL is limited, but safety and efficacy data are encouraging, suggesting that it may be possible to use CAR T cells in populations of CLL patients with particularly unfavorable prognoses. Mechanisms intrinsic to the pathophysiology of CLL undoubtedly explain the efficacy reported based on limited data for the first few series, and underlie the rationale of successive modulations in lymphodepletion schemes, transgene constructs, and, finally, the therapeutic association of CAR T cells with ibrutinib, which appears to be particularly promising. This review describes the published results and expected developments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available